Vitruvias Therapeutics, Inc.

Vitruvias Therapeutics, Inc. focuses on developing and distributing generic pharmaceuticals, providing essential medications for various health conditions, thereby enhancing access to vital treatments for healthcare providers and patients alike. Founded in 2013 and headquartered in Auburn, US, Vitruvias Therapeutics, Inc. is involved in the production of generic drugs.

The company's founders, Bryce Harvey and Carl Whatley, have established a firm that has made three deals since inception. The most recent funding round occurred on January 5, 2018, when the company raised USD 11. 5 mn in a Series A round led by JW Asset Management and Perceptive Advisors, bringing the total amount raised to USD 11. 5 mn.

Vitruvias Therapeutics specializes in developing and distributing generic pharmaceuticals, including Aminocaproic Acid Tablets, Cyanocobalamin Injection, Propafenone Hydrochloride Extended-Release Capsules, Pramipexole Dihydrochloride Extended-Release Tablets, and Bupropion Hydrochloride Extended-Release Tablets. These products address critical health conditions such as bleeding disorders, vitamin deficiencies, cardiac arrhythmias, Parkinson's disease, and depression. The company serves a range of clients, including healthcare providers, hospitals, and pharmacies in the U. S.

and aims for potential international markets. The revenue of Vitruvias Therapeutics is mainly derived from business-to-business transactions with healthcare organizations, pharmacies, and wholesalers through bulk orders and contracts. The company forms strategic partnerships with smaller global firms to enhance their access to the U. S.

pharmaceutical landscape, employing competitive pricing strategies for their generic products, which are typically lower than branded options. Revenue flows primarily through direct sales to healthcare providers and wholesalers, avoiding reliance on consumer-facing retail strategies. In January 2018, Vitruvias Therapeutics, Inc. secured USD 11.

5 mn in Series A financing aimed at supporting the development of new generic product lines and expanding market reach. The company is focused on launching additional medications to address unmet medical needs and intends to explore international markets for distribution. Specific geographic regions for expansion have not been disclosed, but efforts are in place to leverage recent funding for enhancing product offerings and entering new markets.